SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

NCT05307328 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Cushing's Syndrome I
Cushing Disease Due to Increased ACTH Secretion
Cortisol Excess
Cortisol; Hypersecretion
Cortisol Overproduction
Ectopic ACTH Secretion

Interventions

DRUG: SPI-62
DRUG: Placebo

Sponsor

Sparrow Pharmaceuticals